21st Annual NATA Symposium Scientific Programme
SESSION 1A
SAFETY OF BLOOD AND BLOOD PRODUCTS
Chairs: TBD
Transfusion-related immunomodulation – theoretical or clinically relevant?
David Baron, Vienna, Austria
Pathogen testing in 2021 – what is necessary?
Maria Beatrice Rondinelli, Rome, Italy
Age of blood – problem solved or ongoing debate?
Philip C. Spinella, St. Louis, MO, USA
Discussion
SESSION 2A
HOT TOPICS I – CLINICAL TRANSFUSION PRACTICE
Chairs: TBD
How to approach liberal vs. restrictive transfusion
Anders Møller, Slagelse, Denmark
Transfusion strategy in myocardial infarction – REALITY trial
Philippe Gabriel Steg, Paris, France
Whole blood – now or never?
Jakob Stensballe, Copenhagen, Denmark
Discussion
SESSION 3A
PATIENT BLOOD MANAGEMENT – WHAT I HAVE TO KNOW AS A TRAINEE
Chairs: TBD
The basics of PBM – pillar 1
Ane Abad Motos, Madrid, Spain
The basics of PBM – pillar 2
Dania Fischer, Frankfurt, Germany
The basics of PBM – pillar 3
Tina Tomić Mahečić, Zagreb, Croatia
Discussion
SESSION 4A
HOT TOPICS II – PBM RESEARCH AND IMPLEMENTATION
Chairs: TBD
Top 5 most important PBM publications in 2020–2021
David Faraoni, Toronto, ON, Canada
RCTs in PBM – do they give us all the answers?
Axel Hofmann, Zurich, Switzerland
Maturity Assessment in PBM – monitoring implementation at the national level
Elvira Bisbe, Barcelona, Spain
Discussion
SESSION 3A
PATIENT BLOOD MANAGEMENT – WHAT I HAVE TO KNOW AS A TRAINEE
Chairs: TBD
The basics of PBM – pillar 1
Ane Abad Motos, Madrid, Spain
The basics of PBM – pillar 2
Dania Fischer, Frankfurt, Germany
The basics of PBM – pillar 3
Tina Tomić Mahečić, Zagreb, Croatia
Discussion
SESSION 4B
HOT TOPICS II – PBM RESEARCH AND IMPLEMENTATION
Chairs: TBD
Top 5 most important PBM publications in 2020–2021
David Faraoni, Toronto, ON, Canada
RCTs in PBM – do they give us all the answers?
Axel Hofmann, Zurich, Switzerland
Maturity Assessment in PBM – monitoring implementation at the national level
Elvira Bisbe, Barcelona, Spain
Discussion
SESSION 1B
SAFETY OF BLOOD AND BLOOD PRODUCTS
Chairs: TBD
Transfusion-related immunomodulation – theoretical or clinically relevant?
David Baron, Vienna, Austria
Pathogen testing in 2021 – what is necessary?
Maria Beatrice Rondinelli, Rome, Italy
Age of blood – problem solved or ongoing debate?
Philip C. Spinella, St. Louis, MO, USA
Discussion
SESSION 2B
HOT TOPICS I – CLINICAL TRANSFUSION PRACTICE
Chairs: TBD
How to approach liberal vs. restrictive transfusion
Anders Møller, Slagelse, Denmark
Transfusion strategy in myocardial infarction – REALITY trial
Philippe Gabriel Steg, Paris, France
Whole blood – now or never?
Jakob Stensballe, Copenhagen, Denmark
Discussion
SESSION 5A
CELL SALVAGE – OUTDATED OR UP TO DATE?
Chairs: TBD
Cell salvage in paediatrics
Susan M. Goobie, Boston, MA, USA
Cell salvage in the bleeding trauma patient
Lidia Mora Miquel, Barcelona, Spain
Cell salvage in cancer surgery – a no go?
Timo Seyfried, Regensburg, Germany
Discussion
SESSION 6A
HOT TOPICS III – PERIOPERATIVE ANAEMIA AND IRON DEFICIENCY
Chairs: TBD
The anaemia clinic – a must for every hospital
Elvira Bisbe, Barcelona, Spain
Preoperative IV iron in major abdominal surgery: PREVENTT trial
Toby Richards, Perth, WA, Australia
EPO – a new kid on the block?
Sigismond Lasocki, Angers, France
Discussion
SESSION 7A
PATIENT BLOOD MANAGEMENT – A POLITICAL ISSUE?
Chairs: TBD
WHO Action framework for blood products – focus on PBM
Yuyun Maryuningsih, Geneva, Switzerland
Role of the European Union in promoting PBM
TBD
PBM – a spectre for blood bankers?
TBD
Discussion
SESSION 8
SABM SESSION – A PRACTICAL APPROACH TO PATIENT BLOOD MANAGEMENT
Chairs: TBD
The role of the surgeon in PBM
Pierre Tibi, Prescott, AZ, USA
The role of a PBM coordinator
Sherri Ozawa, Englewood, NJ, USA
Wind of change – how to initiate PBM in real life?
Aryeh Shander, Englewood, NJ, USA
Wind of change – how to initiate PBM in real life?
Discussion
SESSION 7B
PATIENT BLOOD MANAGEMENT – A POLITICAL ISSUE?
Chairs: TBD
WHO Action framework for blood products – focus on PBM
Yuyun Maryuningsih, Geneva, Switzerland
Role of the European Union in promoting PBM
TBD
PBM – a spectre for blood bankers?
TBD
Discussion
SESSION 9
ASPBM SESSION
Chairs: TBD
TBD
TBD
TBD
TBD
TBD
TBD
Discussion
SESSION 10A
PATIENT BLOOD MANAGEMENT IN THE ICU
Chairs: TBD
Role of iron and EPO in the ICU
Sigismond Lasocki, Angers, France
Coagulopathies in the ICU
Isabell Pekrul, Munich, Germany
Transfusion triggers for critically ill patients – ESICM guidelines
Alexander P. J. Vlaar, Amsterdam, The Netherlands
Discussion
SESSION 11A
HOT TOPICS IV – BLEEDING AND THROMBOSIS
Chairs: TBD
When to use tranexamic acid?
Beverley J. Hunt, London, UK
Point-of-care coagulation monitoring – the way to go
Jakob Stensballe, Copenhagen, Denmark
COVID-19, haemostasis and thrombosis
Charles-Marc Samama, Paris, France
Discussion
SESSION 7B
PATIENT BLOOD MANAGEMENT – A POLITICAL ISSUE?
Chairs: TBD
WHO Action framework for blood products – focus on PBM
Yuyun Maryuningsih, Geneva, Switzerland
Role of the European Union in promoting PBM
TBD
PBM – a spectre for blood bankers?
TBD
Discussion
SESSION 9
ASPBM SESSION
Chairs: TBD
TBD
TBD
TBD
TBD
TBD
TBD
Discussion
SESSION 10A
PATIENT BLOOD MANAGEMENT IN THE ICU
Chairs: TBD
Role of iron and EPO in the ICU
Sigismond Lasocki, Angers, France
Coagulopathies in the ICU
Isabell Pekrul, Munich, Germany
Transfusion triggers for critically ill patients – ESICM guidelines
Alexander P. J. Vlaar, Amsterdam, The Netherlands
Discussion
SESSION 11A
HOT TOPICS IV – BLEEDING AND THROMBOSIS
Chairs: TBD
When to use tranexamic acid?
Beverley J. Hunt, London, UK
Point-of-care coagulation monitoring – the way to go
Jakob Stensballe, Copenhagen, Denmark
COVID-19, haemostasis and thrombosis
Charles-Marc Samama, Paris, France